Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA6 | P23280 | 2/20 | 0.62 |
| ▸ | CA5A | P35218 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | JUN | P05412 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552823 | 1.00 | MAOB (0.63) | MAOBCA12CA4CA6CA5A | |
| SCHEMBL1551528 | 0.90 | MAOB (0.60) | MAOBCA12CA4CA6CA5A | |
| SCHEMBL1551530 | 0.90 | MAOB (0.60) | MAOBCA12CA4CA6CA5A | |
| SCHEMBL1552561 | 0.88 | MAOB (0.69) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL1552227 | 0.88 | MAOB (0.69) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL13678116 | 0.84 | ALDH1A1 (0.59) | MAOBCA12CA4CA6CA5A | |
| SCHEMBL4477433 | 0.83 | MAOB (0.77) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL4477440 | 0.83 | MAOB (0.77) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL13678109 | 0.82 | ALDH1A1 (0.56) | MAOBCA12CA4CA6CA5A | |
| SCHEMBL13678101 | 0.81 | MAOB (0.78) | MAOBMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563820-B2 | Compounds for modulating cell proliferation | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-07-21 | — | — | US | claimed |
| US-20070197660-A1 | Compounds for modulating cell proliferation | THE HOSPITAL FOR SICK CHILDREN (CA) | 2007-08-23 | — | — | US | claimed |
| EP-1654220-A4 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | HOSPITAL FOR SICK CHILDREN (CA) | 2006-10-25 | — | — | EP | claimed |
| EP-1654220-A1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | The Hospital for Sick Children (CA) | 2006-05-10 | — | — | EP | claimed |
| WO-2005012234-A1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | THE HOSPITAL FOR SICK CHILDREN (CA) | 2005-02-10 | — | — | WO | claimed |
| EP-1467967-A1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | The Hospital for Sick Children (CA) | 2004-10-20 | — | — | EP | claimed |
| WO-2003062190-A1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | THE HOSPITAL FOR SICK CHILDREN (CA) | 2003-07-31 | — | — | WO | claimed |
| EP-1467967-B1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | HOSPITAL FOR SICK CHILDREN (CA) | 2011-04-27 | — | — | EP | disclosed |
| US-7563820-B2 | Compounds for modulating cell proliferation | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-07-21 | — | — | US | disclosed |
| US-20070197660-A1 | Compounds for modulating cell proliferation | THE HOSPITAL FOR SICK CHILDREN (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20060241084-A1 | Inhibition of vascular endothelial growth factor | THE HOSPITAL FOR SICK CHILDREN (CA) | 2006-10-26 | — | — | US | disclosed |
| EP-1654220-A4 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | HOSPITAL FOR SICK CHILDREN (CA) | 2006-10-25 | — | — | EP | disclosed |
| EP-1654220-A1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | The Hospital for Sick Children (CA) | 2006-05-10 | — | — | EP | disclosed |
| EP-1551381-A2 | STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR | The Hospital for Sick Children (CA) | 2005-07-13 | — | — | EP | disclosed |
| US-20050085538-A1 | Compounds for modulating cell proliferation | HOSPITAL FOR SICK CHILDREN, THE (CA) | 2005-04-21 | — | — | US | disclosed |
| WO-2005012234-A1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | THE HOSPITAL FOR SICK CHILDREN (CA) | 2005-02-10 | — | — | WO | disclosed |
| EP-1467967-A1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | The Hospital for Sick Children (CA) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004032911-A2 | STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR | THE HOSPITAL FOR SICK CHILDREN (CA) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003062190-A1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | THE HOSPITAL FOR SICK CHILDREN (CA) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241084-A1 | Inhibition of vascular endothelial growth factor | VEGFA, FLT4, FLT1 | MAOB 495/4885CA12 1078/4885CA4 443/4885 |
| US-20050085538-A1 | Compounds for modulating cell proliferation | CCNO, CCNY, CCND3 | MAOB 1268/4885CA12 3311/4885CA4 2060/4885 |
| US-20070197660-A1 | Compounds for modulating cell proliferation | CCND3, CCNO, WNT3 | MAOB 2008/4885CA12 2365/4885CA4 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.